Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al
This dosage chart is a tool for monitoring progress
Key safety considerations include: Absolute contraindications: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [1] Important warnings and precautions: Not recommended in patients with severe gastroparesis IBS-specific assessment: Dehydration risk increases when gastrointestinal side effects occur, particularly with diarrhea or persistent nausea limiting fluid intake
doi: 10.3389/fendo.2025.1624001 Received 06 May 2025 Accepted 17 June 2025 Published 04 July 2025 Volume 16 - 2025 Edited by Valeria Guglielmi, Policlinico Tor Vergata, Italy Reviewed by Ilaria Milani, Sapienza University of Rome, Italy Jenny Pena Dias, Johns Hopkins University, United States Updates Copyright 2025 Andrade, Lobato, Machado, Hartmann, Holst, Almeida, Nora, Monteiro, Guimares and Pereira